GO:2000124 regulation of endocannabinoid signaling pathway: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000124 describes any process that modulates the frequency, rate, or extent of endocannabinoid signaling, a lipid-based retrograde messenger system.
• Endocannabinoid signaling is regulated by stress, glucocorticoids, and synaptic activity, with impacts on anxiety, depression, and the hypothalamic-pituitary-adrenal axis.
• Key genes include CB1R (CNR1), CB2R (CNR2), FAAH, MAGL, DAGL, and NAPE-PLD, which control synthesis, degradation, and receptor activation.
• Dysregulation of this pathway is implicated in psychiatric disorders, rheumatoid arthritis, intestinal inflammation, and microglial neuroinflammation.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of endocannabinoid regulatory genes in vitro and in vivo.
• Understanding GO:2000124 aids target discovery for pharmacotherapy aimed at mitigating destructive events in disease.
Description
The Gene Ontology term GO:2000124, regulation of endocannabinoid signaling pathway, refers to any process that modulates the frequency, rate, or extent of endocannabinoid signaling. Endocannabinoids are lipid messengers synthesized on demand that act primarily through cannabinoid receptors CB1 and CB2 to regulate synaptic transmission, inflammation, and energy balance. Because this signaling system is dynamically regulated by neuronal activity, stress, and immune cues, its precise control is critical for homeostasis. Researchers study GO:2000124 to understand how perturbations in endocannabinoid tone contribute to psychiatric, inflammatory, and metabolic diseases. The pathway is a promising therapeutic target, and its regulatory mechanisms are being dissected using genetic and pharmacological tools. This article synthesizes current knowledge from QuickGO and verified PubMed literature to provide a research-grade overview of GO:2000124.
regulation of endocannabinoid signaling pathway At A Glance
| GO ID | GO:2000124 |
|---|---|
| GO term | regulation of endocannabinoid signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of endocannabinoid signalling pathway |
| Major function | Modulates the frequency, rate, or extent of endocannabinoid signaling |
| Key receptors | Cannabinoid receptors CB1 (CNR1) and CB2 (CNR2) |
| Major endocannabinoids | Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) |
| Synthesis enzymes | NAPE-PLD for AEA; DAGL for 2-AG |
| Degradation enzymes | FAAH for AEA; MAGL for 2-AG |
What Is GO:2000124?
In our own words, GO:2000124 encompasses all biological processes that adjust the strength, duration, or location of endocannabinoid signaling. This includes regulation of endocannabinoid synthesis, release, receptor binding, and degradation, as well as modulation of downstream signaling cascades. The term is a biological process and is synonymous with regulation of endocannabinoid signalling pathway.
Why Is regulation of endocannabinoid signaling pathway Important in Cell Biology?
Regulation of endocannabinoid signaling is essential for maintaining physiological balance in the nervous, immune, and gastrointestinal systems. Dysregulation of this pathway is linked to anxiety, depression, chronic stress, rheumatoid arthritis, and intestinal inflammation. Understanding GO:2000124 provides mechanistic insight into how cells adjust endocannabinoid tone in response to environmental and pathological challenges, informing therapeutic strategies.
• Modulates synaptic plasticity and emotional behavior, with implications for anxiety and depression.
• Controls stress responses via glucocorticoid-mediated negative feedback on the hypothalamic-pituitary-adrenal axis.
• Regulates immune cell function and inflammation in rheumatoid arthritis.
• Maintains intestinal homeostasis and barrier function.
• Shapes microglial activity and neuroinflammation.
• Provides targets for pharmacotherapy in psychiatric and inflammatory diseases.
• Influences pain perception and reward processing through CB1 receptor signaling.
• Interacts with metabolic and endocrine pathways to regulate energy balance.
• Serves as a model for lipid retrograde signaling in the brain.
• Offers opportunities for CRISPR-based functional genomics of regulatory enzymes.
What Happens During regulation of endocannabinoid signaling pathway?
Endocannabinoid Synthesis and Release
In simple terms: Cells make endocannabinoids on demand and release them to send signals.
Endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are synthesized postsynaptically in response to neuronal activity and calcium influx. NAPE-PLD and DAGL are key enzymes for AEA and 2-AG production, respectively. Regulation of synthesis determines the availability of these lipid messengers for signaling.
Receptor Activation and Signal Transduction
In simple terms: Endocannabinoids bind to receptors on target cells to trigger responses.
AEA and 2-AG act primarily through CB1 and CB2 receptors, which are Gi/o-coupled and inhibit adenylyl cyclase and modulate ion channels. CB1 is abundant in the brain, while CB2 is mainly in immune cells. Activation of these receptors regulates neurotransmitter release and immune cell activity.
Endocannabinoid Degradation and Termination
In simple terms: Enzymes break down endocannabinoids to stop the signal.
FAAH hydrolyzes AEA, and MAGL hydrolyzes 2-AG, terminating their signaling. Regulation of these degradative enzymes controls the duration and intensity of endocannabinoid actions. Inhibitors of FAAH and MAGL are being explored for therapeutic purposes.
Stress and Glucocorticoid Regulation
In simple terms: Stress hormones can change how endocannabinoids work.
Stress and glucocorticoids regulate endocannabinoid signaling, which in turn provides negative feedback on the hypothalamic-pituitary-adrenal axis. This feedback loop is critical for stress adaptation and emotional regulation. Dysregulation contributes to stress-related affective disorders.
Microglial and Immune Modulation
In simple terms: Endocannabinoids help control immune cells in the brain and body.
Endocannabinoid signaling in microglia regulates neuroinflammatory responses. In the intestine, it contributes to homeostasis and barrier function. In rheumatoid arthritis, modulation of the endocannabinoid system may mitigate destructive inflammatory events.
Key Genes Involved in GO:2000124 regulation of endocannabinoid signaling pathway
The following genes encode core components and regulators of the endocannabinoid signaling pathway, as documented in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Encodes CB1 receptor, mediates central effects of endocannabinoids | Target for psychiatric and metabolic studies |
| CNR2 | Encodes CB2 receptor, mainly immune cells | Target for inflammation and arthritis research |
| FAAH | Degrades anandamide | Inhibitor studies for pain and anxiety |
| MGLL | Degrades 2-AG | Target for neuroinflammation and pain |
| DAGLA | Synthesizes 2-AG | Role in synaptic plasticity |
| DAGLB | Synthesizes 2-AG | Potential redundancy with DAGLA |
| NAPEPLD | Synthesizes anandamide | Genetic models for stress research |
| GPR55 | Putative cannabinoid receptor | Emerging target in inflammation |
| TRPV1 | Ion channel activated by anandamide | Pain and sensory studies |
| PPARG | Nuclear receptor activated by endocannabinoids | Metabolic and anti-inflammatory effects |
| CNR1 (CB1) | Presynaptic inhibition of neurotransmitter release | Anxiety and depression models |
| CNR2 (CB2) | Modulates cytokine release | Rheumatoid arthritis models |
| FAAH | Hydrolyzes AEA | Knockout mice show elevated AEA |
| MGLL | Hydrolyzes 2-AG | Knockout mice show elevated 2-AG |
| DAGL | Diacylglycerol lipase | Retrograde signaling studies |
| NAPE-PLD | N-acyl phosphatidylethanolamine phospholipase D | AEA synthesis regulation |
| ABHD6 | Serine hydrolase degrading 2-AG | Potential therapeutic target |
| ABHD12 | Serine hydrolase degrading 2-AG | Neuroinflammatory research |
How Is regulation of endocannabinoid signaling pathway Regulated?
Endocannabinoid signaling is regulated at multiple levels, including synthesis, release, receptor expression, and degradation. Stress and glucocorticoids modulate endocannabinoid tone, which provides negative feedback on the HPA axis. In microglia, endocannabinoid signaling is dynamically regulated during neuroinflammation. Intestinal homeostasis also depends on proper regulation of this pathway.
regulation of endocannabinoid signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Anxiety and depression | Conditional knockout mice, overexpression in septohabenular pathway |
| CNR2 | Rheumatoid arthritis | Knockout rats, point mutation for ligand binding |
| FAAH | Pain and affective disorders | Knock-in of human variant, knockout mice |
| MGLL | Neuroinflammation | Microglia-specific knockout, overexpression |
| NAPEPLD | Stress-related disorders | Knockout mice, CRISPR point mutation |
Psychiatric Disorders: Anxiety and Depression
Dysregulation of endocannabinoid signaling in septohabenular pathways is associated with anxiety- and depressive-like behaviors. Integrating endocannabinoid signaling in the regulation of anxiety and depression highlights its therapeutic potential. Stress-related affective disorders involve altered endocannabinoid regulation.
Rheumatoid Arthritis
The endocannabinoid signaling pathway is an emerging target in pharmacotherapy for rheumatoid arthritis, aiming to mitigate destructive inflammatory events. Modulation of CB2 and other components may reduce joint damage.
Intestinal Inflammation and Homeostasis
The endocannabinoid system plays a key role in regulating intestinal homeostasis, and its dysregulation contributes to inflammatory bowel diseases. Targeting this pathway may restore barrier function.
Neuroinflammation and Microglial Activation
Endocannabinoid signaling in microglia modulates neuroinflammatory responses, and its dysregulation is implicated in neurodegenerative conditions. Regulating microglial endocannabinoid tone may be protective.
From regulation of endocannabinoid signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FAAH alter anxiety-like behavior? | FAAH knockout mouse |
| Does CB1 receptor point mutation affect ligand binding? | CRISPR knock-in of mutant CNR1 |
| Can overexpression of DAGL increase 2-AG levels? | Lentiviral overexpression in neurons |
| What is the role of microglial CB2 in neuroinflammation? | Microglia-specific conditional knockout |
| Does NAPE-PLD regulate HPA axis feedback? | NAPE-PLD knockout mice |
| Can CRISPR library screening identify regulators of endocannabinoid signaling? | Genome-wide CRISPR knockout screen in cell lines |
How to Study the regulation of endocannabinoid signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | FAAH, MGLL, CNR1 knockout cells |
| CRISPR knock-in | Precise point mutations | Receptor binding studies |
| Overexpression | Gain of function | DAGL or NAPE-PLD overexpression |
| Lipidomics | Endocannabinoid levels | AEA and 2-AG quantification |
| Behavioral tests | Anxiety/depression-like behavior | Knockout mouse phenotyping |
| Electrophysiology | Synaptic transmission | CB1-mediated effects |
| CRISPR library screening | Identify novel regulators | Genome-wide screens |
| Bioinformatics | Pathway enrichment | Integrative analysis |
Genetic Knockout and Knock-in Models
CRISPR-Cas9 knockout of genes such as FAAH, MGLL, or CNR1 enables causal testing of their roles in endocannabinoid signaling. Knock-in of point mutations can dissect receptor-ligand interactions.
Pharmacological and Lipidomic Profiling
Measuring endocannabinoid levels by mass spectrometry after genetic manipulation reveals changes in synthesis and degradation. Selective inhibitors of FAAH and MAGL are used to validate targets.
Behavioral and Electrophysiological Assays
Anxiety- and depressive-like behaviors in rodents are assessed after manipulating endocannabinoid genes. Electrophysiology can measure synaptic effects of altered endocannabinoid tone.
CRISPR Library Screening and Bioinformatics
Genome-wide CRISPR screens can identify novel regulators of endocannabinoid signaling. Bioinformatics integration of transcriptomic and lipidomic data helps prioritize candidates.
How CRISPR Can Be Used to Study GO:2000124 regulation of endocannabinoid signaling pathway
Knockout
CRISPR knockout of endocannabinoid-related genes such as CNR1, CNR2, FAAH, and MGLL provides definitive loss-of-function models to study regulation of signaling. These models are used in behavioral, inflammatory, and metabolic assays.
Point Mutation
Point mutations introduced by CRISPR base editing or HDR can mimic human variants in genes like FAAH or CNR1, allowing precise structure-function studies. Such models help dissect ligand binding and enzyme kinetics.
Knock-in
Knock-in of reporter tags or humanized alleles enables tracking of endocannabinoid enzymes and receptors in vivo. This approach is valuable for imaging and biochemical studies.
Overexpression
CRISPR activation or lentiviral overexpression of DAGL, NAPE-PLD, or CB1 can elevate endocannabinoid tone and test gain-of-function phenotypes. Overexpression models are useful for target validation.
How EDITGENE Supports regulation of endocannabinoid signaling pathway Research
Researchers studying regulation of endocannabinoid signaling pathway-related genes often need to determine whether a candidate gene is causally involved in synthesis, degradation, receptor activation, or downstream modulation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this functional genomics workflow.
Contact EDITGENE today to design your custom CRISPR model for regulation of endocannabinoid signaling pathway research.
Frequently Asked Questions About regulation of endocannabinoid signaling pathway
What is GO:2000124?
GO:2000124 is the Gene Ontology term for regulation of endocannabinoid signaling pathway, defined as any process that modulates the frequency, rate, or extent of endocannabinoid signaling.
What genes are involved in regulation of endocannabinoid signaling pathway?
Key genes include CNR1, CNR2, FAAH, MGLL, DAGLA, DAGLB, NAPEPLD, and others encoding receptors, synthesizing and degrading enzymes.
How is endocannabinoid signaling regulated by stress?
Stress and glucocorticoids regulate endocannabinoid signaling, which provides negative feedback on the HPA axis.
What diseases are associated with dysregulation of endocannabinoid signaling?
Anxiety, depression, rheumatoid arthritis, intestinal inflammation, and neuroinflammation are linked to dysregulation.
What are the main endocannabinoids?
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the primary endocannabinoids.
How can CRISPR be used to study endocannabinoid signaling?
CRISPR knockout, knock-in, point mutation, and overexpression models enable functional dissection of genes in this pathway.
What is the role of CB1 receptor in endocannabinoid signaling?
CB1 receptor mediates central effects of endocannabinoids, including modulation of neurotransmitter release.
What is the role of CB2 receptor?
CB2 receptor is mainly expressed in immune cells and modulates inflammatory responses.
Which enzymes degrade endocannabinoids?
FAAH degrades anandamide, and MAGL degrades 2-AG.
How does endocannabinoid signaling affect microglia?
Endocannabinoid signaling in microglia regulates neuroinflammatory responses.
Conclusion
GO:2000124, regulation of endocannabinoid signaling pathway, is a critical biological process that controls lipid messenger tone in the nervous, immune, and gastrointestinal systems. Its dysregulation contributes to psychiatric, inflammatory, and metabolic diseases, making it a prime target for therapeutic intervention. CRISPR-based functional genomics, combined with lipidomics and behavioral assays, offers powerful tools to dissect the regulatory mechanisms and identify novel drug targets. Continued research into this pathway will advance our understanding of endocannabinoid biology and its clinical applications.
References
- 1. Vickstrom CR et al.. 2021. Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior.. Mol Psychiatry 26(7):3178-3191 PMID: 33093652
- 2. Yin AQ et al.. 2019. Integrating endocannabinoid signaling in the regulation of anxiety and depression.. Acta Pharmacol Sin 40(3):336-341 PMID: 30002489
- 3. Kaur I et al.. 2020. The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis.. Life Sci 257:118109 PMID: 32698072
- 4. Marinelli S et al.. 2023. Endocannabinoid signaling in microglia.. Glia 71(1):71-90 PMID: 36222019
- 5. Kilaru A et al.. 2020. The endocannabinoid system.. Essays Biochem 64(3):485-499 PMID: 32648908
- 6. Gorzalka BB et al.. 2008. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.. Neurosci Biobehav Rev 32(6):1152-60 PMID: 18433869
- 7. Hill MN et al.. 2012. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis.. Neuroscience 204:5-16 PMID: 22214537
- 8. Cuddihey H et al.. 2022. Role of the Endocannabinoid System in the Regulation of Intestinal Homeostasis.. Cell Mol Gastroenterol Hepatol 14(4):947-963 PMID: 35750314
